期刊文献+

某院24例亚胺培南/西司他丁不良反应报告分析 被引量:3

Analysis of 24 adverse reactions of imipenem-cilastatin in a hospital
下载PDF
导出
摘要 目的分析某院近5年亚胺培南/西司他丁发生的不良反应(ADRS),为临床合理用药提供参考。方法回顾性调查某院2015年1月~2020年5月上报的亚胺培南/西司他丁所致ADRS 24例并进行统计分析。结果亚胺培南/西司他丁常见ADRS为谵语、躁动不安、幻觉、胃肠道反应,老年患者更易发生,男性多于女性。结论中枢神经系统副作用为亚胺培南/西司他丁最常见的ADRS,临床应用应高度重视,提高临床用药安全意识。 Objective To analyze the adverse drug reactions(ADRS)caused by Imipenem-cilastatin in recently 5years in our hospital and provide reference for clinical rational drug using.Methods A retrospective study on 24 ADRS induced by Imipenem-cilastatin in our hospital from January 2015 to May 2020.Results The common ADRS of Imipenem-cilastatin were delirium,restlessness,hallucinations and gastrointestinal reactions.Older patients were more susceptible and male were more than female.Conclusion The central nervous system side effect is the most common ADRS of Imipenem-cilastatin,high attention should be paid to clinical application,awareness of clinical safety medication should be increased.
作者 陈聪聪 董博 CHEN Cong-cong;DONG Bo(The first affiliated hospital of Baotou medical college,Inner Mongolia university of science and technology,Inner Mongolia 014010,China;不详)
出处 《中国处方药》 2021年第2期61-62,共2页 Journal of China Prescription Drug
关键词 亚胺培南/西司他丁 不良反应 分析 Imipenem-cilastatin Adverse reaction Analysis
  • 相关文献

参考文献4

二级参考文献39

  • 1周颖杰,李光辉.成人及儿童复杂性腹腔内感染的诊断与处理:美国外科感染学会及美国感染病学会指南[J].中国感染与化疗杂志,2010,10(4):241-247. 被引量:238
  • 2程叙扬,王梅,姜瑞凤.抗菌药物致慢性肾衰患者神经精神症状12例分析[J].药物不良反应杂志,2004,6(3):156-160. 被引量:25
  • 3Wallace KL. Antibiotic-induced convulsions [ J ]. Crit Care Clin, 1997,13(4) :741-763.
  • 4Koppel BS, Hauser WA, Politis C, et al. Seizures in the Critically III: The Role of Imipenem [ J ]. Epilepsia, 2001, 42(12) :1590 - 1593.
  • 5Livermore DM, Sefton AM, Scott GM. Properties and potential of ertapenem [ J ]. J Antimicrob Chemother, 2003, 52(3) :331 -344.
  • 6Scfaliamser SE, Brobohn KA, Liljedahl AL, et al. Comparative neurotoxicity of benzylpenicillin, imipenem/ cilastatin and FCE 22101, a new injectible penem[ J]. J Antimicrob Chemother, 1988, 22 (5) :687-695.
  • 7Cirillo I, Vaccaro N, Solanki B, et al. Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers [ J ]. J Clin Pharmacol, 2009, 49 (7) : 798-806.
  • 8Paterson DL, Depestel DD. Doripenem [ J ]. Clin Infect Dis, 2009, 49(2) :291 - 298.
  • 9Mandell L. Doripenem: a new carbapenem in the treatment of nosocomial infection[ J ]. Clin Infect Dis, 2009, 49(Suppl 1) :S1 -S3.
  • 10Redman R, File TM. Safety of intravenous infusion of doripenem[J]. Clin Infect Dis, 2009, 49 (Suppl 1): S28-S35.

共引文献122

同被引文献35

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部